Imat 100mg Tablet

Imat 100mg tablet is an anti-cancer medication. It is used in the treatment of several types of blood cancer, including Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Gastrointestinal Stromal Tumors (GISTs). The medication's active ingredient is Imatinib, which belongs to the class group of Tyrosine kinase inhibitors. The medicine works by inhibiting he BCR- ABL tyrosine kinase enzyme, which is responsible for the growth of cancer cells in the body. Dosage and duration is correctly administered by the healthcare professional.

• Chronic Myeloid Leukemia (CML),
• Acute Lymphoblastic Leukemia (ALL)
• Gastrointestinal Stromal Tumors (GISTs)

Imat 100mg tablet contains various types of side effects, some are recover on their, and some need proper medical attention to treat. Common ones include:

• Muscle cramps and pain
• Diarrhea
• Skin rash, night sweats
• Tiredness, dizziness
• Abdominal pain
• Increased weight
• Decreased RBC and WBC cells
• Headache
• Cough, Inflammation in the nose
• Fever, lack of sleep

• Heart failure
• GI disorders
• Hypothyroidism
• Liver failure
• Swelling in the body
• Swelling in the face, legs, ankles, and feet
• Nausea, vomiting

Doctor suggest to take Imat 100mg tablet with or without food, preferably at the same time every day. Usually, the dose should be taken orally with a whole glass of water. Do not adjust according to your need; always consult a healthcare professional before using the medication to avoid complications during the treatment.

Imat 100mg tablet helps control disease progression by inhibiting the BCR- ABL tyrosine kinase enzyme,  which is responsible for the uncontrolled growth of cancer cells in the body. By blocking the enzyme, the medicine helps stop the proliferation of malignant cells. As a result, it stops the cancer cells from spreading to other body parts and prevents the body from further growing tumors in the body.

• Peng, B., Lloyd, P., & Schran, H. (2005). Clinical pharmacokinetics of imatinib. Clinical pharmacokinetics, 44(9), 879-894. https://pubmed.ncbi.nlm.nih.gov/16122278/
• Buchdunger, E., O'Reilley, T., & Wood, J. (2002). Pharmacology of imatinib (STI571). European journal of cancer, 38, S28-S36. https://pubmed.ncbi.nlm.nih.gov/12528770/
• Nikolova, Z., Peng, B., Hubert, M., Seiberling, M., Keller, U., Ho, Y. Y., ... & Capdeville, R. (2004). Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer chemotherapy and pharmacology, 53(5), 433-438. https://pubmed.ncbi.nlm.nih.gov/15132131/
• BOGURADZKI, P. BIOEQUIVALENCE STUDY OF 400 AND 100 MG IMATINIB FILM-COATED TABLETS IN HEALTHY VOLUNTEERS. https://pubmed.ncbi.nlm.nih.gov/25362813/
• Ma, Z., Zhao, J., Li, S., Gao, F., Zhang, C., Wu, L., & Lin, Y. (2024). Imatinib-induced ulcerative colitis. Journal of Oncology Pharmacy Practice, 30(6), 1111-1117. https://pubmed.ncbi.nlm.nih.gov/38772691/